JP2024521164A - 感染後自己免疫性糖尿病を治療するための方法 - Google Patents

感染後自己免疫性糖尿病を治療するための方法 Download PDF

Info

Publication number
JP2024521164A
JP2024521164A JP2023572868A JP2023572868A JP2024521164A JP 2024521164 A JP2024521164 A JP 2024521164A JP 2023572868 A JP2023572868 A JP 2023572868A JP 2023572868 A JP2023572868 A JP 2023572868A JP 2024521164 A JP2024521164 A JP 2024521164A
Authority
JP
Japan
Prior art keywords
day
teplizumab
dose
diabetes
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572868A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521164A5 (https=
Inventor
レオン，フランシスコ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Provention Bio Inc
Original Assignee
Provention Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provention Bio Inc filed Critical Provention Bio Inc
Publication of JP2024521164A publication Critical patent/JP2024521164A/ja
Publication of JP2024521164A5 publication Critical patent/JP2024521164A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2023572868A 2021-05-24 2022-05-24 感染後自己免疫性糖尿病を治療するための方法 Pending JP2024521164A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163192414P 2021-05-24 2021-05-24
US63/192,414 2021-05-24
PCT/US2022/030780 WO2022251258A1 (en) 2021-05-24 2022-05-24 Methods for treating post infectious autoimmune diabetes
US17/752,650 2022-05-24
US17/752,650 US20220372146A1 (en) 2021-05-24 2022-05-24 Methods for treating post infectious autoimmune diabetes

Publications (2)

Publication Number Publication Date
JP2024521164A true JP2024521164A (ja) 2024-05-28
JP2024521164A5 JP2024521164A5 (https=) 2025-11-05

Family

ID=84104472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572868A Pending JP2024521164A (ja) 2021-05-24 2022-05-24 感染後自己免疫性糖尿病を治療するための方法

Country Status (10)

Country Link
US (1) US20220372146A1 (https=)
EP (1) EP4347021A4 (https=)
JP (1) JP2024521164A (https=)
KR (1) KR20240023522A (https=)
CN (1) CN117794572A (https=)
AU (1) AU2022283272A1 (https=)
CA (1) CA3219473A1 (https=)
IL (1) IL308627A (https=)
MX (1) MX2023013849A (https=)
WO (1) WO2022251258A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
EP4532552A4 (en) * 2022-05-24 2025-10-22 Provention Bio Inc METHODS AND COMPOSITIONS FOR PREVENTING OR DELAYING TYPE 1 DIABETES
TW202506177A (zh) * 2023-03-30 2025-02-16 美商普泛森生技公司 減少外源性胰島素使用之方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
SG177907A1 (en) * 2006-06-14 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
WO2015073833A1 (en) * 2013-11-15 2015-05-21 Pharmacyclics, Inc. Methods for delaying or preventing the onset of type 1 diabetes
WO2020232247A1 (en) * 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CA3148179A1 (en) * 2019-08-20 2021-02-25 Bruce J. Mccreedy Jr. Lymphodepletion dosing regimens for cellular immunotherapies
IL298999A (en) * 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) * 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
EP4532552A4 (en) * 2022-05-24 2025-10-22 Provention Bio Inc METHODS AND COMPOSITIONS FOR PREVENTING OR DELAYING TYPE 1 DIABETES

Also Published As

Publication number Publication date
CN117794572A (zh) 2024-03-29
EP4347021A4 (en) 2025-04-23
IL308627A (en) 2024-01-01
AU2022283272A1 (en) 2023-12-07
US20220372146A1 (en) 2022-11-24
EP4347021A1 (en) 2024-04-10
WO2022251258A1 (en) 2022-12-01
KR20240023522A (ko) 2024-02-22
MX2023013849A (es) 2023-12-08
CA3219473A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
US12565529B2 (en) Methods for treating type 1 diabetes
US20250304688A1 (en) Methods and Compositions Comprising Anti-CD3 Antibodies and DYRK1A Inhibitors for Treating Diabetes
US20220372146A1 (en) Methods for treating post infectious autoimmune diabetes
US12006366B2 (en) Methods and compositions for preventing type 1 diabetes
TW202448505A (zh) 用於治療第1型糖尿病的方法及組成物
KR20190121400A (ko) Ｉｉｉ형 고셔병을 치료하기 위한 조성물 및 방법
JP2026513265A (ja) 外因性インスリン使用を低減するための方法
JP2025517856A (ja) １型糖尿病を予防又は遅延させるための方法及び組成物
TW202434624A (zh) 治療或預防甲狀腺素運載蛋白調節之澱粉樣變性的方法
AU2023329200A1 (en) Pharmaceutical formulation and dosing regimen for the treatment of amyotrophic lateral sclerosis
WO2025024848A1 (en) Methods for treating type 1 diabetes
CN117940162A (zh) 用于治疗糖尿病的包含抗cd3抗体和dyrk1a抑制剂的方法和组合物
CN118591558A (zh) 用于预防或推迟第1型糖尿病的方法及组合物
EP4164689A2 (en) Methods and compositions for preventing type 1 diabetes

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240827

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251027

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260421